No Longer Aiming To Partner At Proof-of-Concept, Flexion Raises $20M For Late-Stage Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Now focused on two key programs in its osteoarthritis portfolio, the Massachusetts drug developer will align itself for a more traditional exit rather than a Big Pharma partnership.